Cleveland BioLabs, Inc. (CBLI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Conditions.
On November 14, 2016, Cleveland BioLabs, Inc. (the Company)
issued a press release announcing its financial results for the
quarter ended September 30, 2016. The information in this Item
2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, except as shall be expressly set forth by
specific reference.
issued a press release announcing its financial results for the
quarter ended September 30, 2016. The information in this Item
2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, except as shall be expressly set forth by
specific reference.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibit
|
No.
|
Description
|
|
99.1
|
Press Release titled Cleveland BioLabs Reports Third
Quarter 2016 Financial Results and Development Progress, dated November 14, 2016 |
About Cleveland BioLabs, Inc. (CBLI)
